Dairy Consumption During a High-intensity, High-volume Training Week in Young Athletes

May 29, 2022 updated by: PKlentrou, Brock University

Our proposed study is a 5-d double-blind randomised cross-over trial, seeking to simulate a training identification camp in competitive adolescent soccer players

The purpose of the proposed study is to investigate whether increased protein consumption by Greek yogurt, compared to an isoenergetic carbohydrate (CHO) control supplement, consumed immediately following exercise training, prior to sleep and between breakfast and lunch, for a week during an intense training period (high volume, high intensity) will:

  • Attenuate the pro-inflammatory response (cytokines, acute phase proteins)
  • Reduced the severity of muscle damage and impairment (creatine kinase)
  • Maintain performance

Secondary outcome measures:

- Increase bone turnover (in favour of formation)

Study Overview

Detailed Description

The proposed study is a randomized, double-blinded, cross-over trial. The protocol will consist of an information session, two identical training camps consisting of 5 consecutive days of intensified soccer training, differing only by nutritional intervention, and identical pre-and post-training session testing. Each testing block will be separated by 28-d to allow for an adequate wash-out and recovery period, during which participants would resume their regular soccer activities

Study Procedures:

All tests and measurements will be performed within eight-weeks. Specifically, participants will attend 1 information session, two identical pre- and post- training/testing sessions and two identical soccer specific training camps.

Information session:

One week prior to the initial soccer specific training camp, participants will be informed of all tests and procedures that will take place and be familiarized with all testing protocols.

Pre- and Post-training testing:

All participants will be tested twice: on the day before (pre) and day following (post) the 5-d soccer specific training camp. Specifically, Participants, will arrive at the University for pre- and post-training testing in the morning at the same time. Body composition measurements will be performed (e.g., standing/seated height, mass, % body fat) followed by fasted venous blood and saliva sampling. A standardized breakfast would then be provided followed by an adequate rest and digest period before performance testing (~1.5h). Performance testing would include a battery of soccer specific tests that cover, power (counter-movement jump, broad jump), speed (10m and 20m sprint), agility (modified 5-0-5) and aerobic capacity (beep-test). During both pre-and-post-testing sessions participants would consume the same standardised breakfast and perform the same tests in the same order for consistency amongst trials which would be repeated between the two testing blocks.

Soccer training:

The simulated 5-d soccer-specific training will be structured to mimic a heavy-volume, high-intensity training camp. Training sessions would occur at the same time each day in the evening for consistency. Drills/exercises will be administered by a certified technical soccer coach and knowledgeable training staff. Each session will began with a 15 min dynamic warm-up followed by 90 min of soccer-specific training, ending with a 15 min cool-down. The 90 min of soccer-specific training will be performed at maximal effort and consist of agility, sprinting and plyometric exercises as well as ball-handling, small-sided games (rondo) and shooting. Following each training session rating of perceived exertion (RPE) will be measured as an indicator of internal load.

Food/Drink supplement consumption:

During the study, three servings of 160 g of 0% plain GY (~115 kcals, 17 g protein, ~11.5 g carbs, 0 fat), or 30 g of isoenergetic CHO (~115 kcal, 0.04 g protein, ~28.6 g carbs, 0 fat) will be provided to participants immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day. The yogurt will be sweetened or flavored with a non-caloric vanilla flavouring to match the taste of the control supplement. The CHO control supplement group will be an isoenergetic dose of a maltodextrin-based semi-solid pudding. This product will be made from non-fat vanilla pudding powder (1 part), maltodextrin (4 parts) and water. This product has been designed to resemble the consistency and texture of Greek yogurt.

Measurements

Questionnaires: Participant Screening and Medical History, Training History, Food frequency Questionnaire (FFQ), sessional RPE.

Anthropometric and body composition measurements: height, seated height, body mass and body fat percentage (%) using bioelectrical impedance analysis (BIA, InBody520; Biospace Co., Ltd., Seoul, S. Korea).

Somatic maturity: maturity offset (years from the age of peak height velocity) will be calculated based on height, seated height and weight measurements.

Exercise performance: will be examined prior to, as well as following each training intervention week. These tests are common in soccer and athletes are familiar with them. To limit confounding exercise influence on both biochemical and performance parameters, participants will be asked to refrain from other activities outside those prescribed to them during the training sessions and 48h prior to the initial pre-assessment visit.

Venous blood and saliva samples: will be collected on 4 separate occasions (24h prior and 24h following the last training session of each training intervention week). To control for circadian rhythm, the exercise session and related blood and saliva samples will be conducted at the same time of day. Saliva samples will be used to examine endocrine response. Venous blood samples will be used to examine inflammatory markers (cytokines - IL-6, IL-10 and TNF-α), c-reactive protein (CRP), IGF-I and indicators of muscle fatigue/damage (CK). Secondary measures may include irisin, oxidative stress (TBARS and ROS) and bone turnover by examining circulating markers of bone formation (PINP, Osteocalcin, BAP, OPG) and of bone resorption (CTX, TRAP, RANKL).

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Welland, Ontario, Canada, L3C 1M6
        • Elite soccer Development

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

11 years to 16 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Participant are female within the desired age ranges (11-16y)
  • Participants are competitive soccer players
  • Previous participation in high-performance training environment (periodization)

Exclusion Criteria:

  • Participant is not female or falls outside of the desired age ranges (11-16y)
  • Chronic/frequent use of medications that could affect inflammatory function - NSAIDS or Corticosteroids.
  • Musculoskeletal injury - resulting in the inability to train and/or perform the baseline/post testing.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Greek Yogurt condition
3x 160g of 0% Plain Greek yogurt (~115 kcals, 17 g protein, ~11.5 g carbs, 0 fat) consumed immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
Female competitive soccer players (11-16y) will consume 0% plain Greek yogurt immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
Placebo Comparator: Isoenergetic condition - Carbohydrate
3x 30g of isoenergetic CHO supplement (~115 kcal, 0.04 g protein, ~28.6 g carbs, 0 fat) consumed immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
Female competitive soccer players (11-16y) will consume an isoenergetic carbohydrate supplement immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body mass (kg)
Time Frame: 8 weeks
Anthropometric measures
8 weeks
Height (cm)
Time Frame: 8 weeks
Anthropometric measures
8 weeks
Seated height (cm)
Time Frame: 8 weeks
Used to calculate maturity offset in years from peak height velocity
8 weeks
Body fat (%)
Time Frame: 8 weeks
Body composition
8 weeks
Rate of perceived exertion
Time Frame: 8 weeks
1-10 scale of perceived exertion
8 weeks
Serum concentrations of BAP (ng/ml)
Time Frame: 8 weeks
Bone formation marker
8 weeks
Serum concentrations of PINP (ng/ml)
Time Frame: 8 weeks
Bone formation marker
8 weeks
Serum concentrations of OPG (pg/ml)
Time Frame: 8 weeks
Bone formation marker
8 weeks
Serum concentrations of CTX (ng/ml)
Time Frame: 8 weeks
Bone resorption marker
8 weeks
Serum concentrations of TRAP (ng/ml)
Time Frame: 8 weeks
Bone resorption marker
8 weeks
Serum concentrations of RANKL (pg/ml)
Time Frame: 8 weeks
Bone resorption marker
8 weeks
Plasma concentrations of irisin (ng/ml)
Time Frame: 8 weeks
Plasma concentrations of pro-and-anti-inflammatory cytokines
8 weeks
Plasma concentrations of IL-6 (pg/ml)
Time Frame: 8 weeks
Plasma concentrations of pro-and-anti-inflammatory cytokines
8 weeks
Plasma concentrations of IL-10 (pg/ml)
Time Frame: 8 weeks
Plasma concentrations of pro-and-anti-inflammatory cytokines
8 weeks
Plasma concentrations of TNF-alpha (pg/ml)
Time Frame: 8 weeks
Plasma concentrations of pro-and-anti-inflammatory cytokines
8 weeks
Plasma concentrations of CRP (pg/ml)
Time Frame: 8 weeks
Plasma concentrations of pro-and-anti-inflammatory cytokines
8 weeks
Plasma concentration of creatine kinase (U/L)
Time Frame: 8 weeks
Muscle damage
8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Serum concentration of IGF-1 (pg/ml)
Time Frame: 8 weeks
Serum concentration of IGF-1
8 weeks
Plasma concentration of TBARS
Time Frame: 8 weeks
Oxidative stress
8 weeks
Plasma concentration of ROS
Time Frame: 8 weeks
Oxidative stress
8 weeks
Saliva concentrations of cortisol (ug/dl)
Time Frame: 8 weeks
Endocrine response
8 weeks
Saliva concentrations of testosterone (pg/ml)
Time Frame: 8 weeks
Endocrine response
8 weeks
Oxidative stress
Time Frame: 8 weeks
Plasma concentrations of markers of oxidative stress
8 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Aerobic Capacity - Beep Test
Time Frame: 8 weeks
Aerobic capacity using the - Beep test; units - distance (m)
8 weeks
Maximal sprint ability
Time Frame: 8 weeks
Maximal sprint ability using a 20 m sprint test; units - time (s)
8 weeks
Explosive leg power - Vertical jump performance
Time Frame: 8 weeks
Explosive leg power using the counter-movement jump; units - height (cm)
8 weeks
Agility and Quickness
Time Frame: 8 weeks
Agility using the 5-10-5 pro-agility test; units - time (s)
8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2019

Primary Completion (Actual)

November 23, 2019

Study Completion (Actual)

November 23, 2019

Study Registration Dates

First Submitted

May 8, 2019

First Submitted That Met QC Criteria

May 9, 2019

First Posted (Actual)

May 13, 2019

Study Record Updates

Last Update Posted (Actual)

June 2, 2022

Last Update Submitted That Met QC Criteria

May 29, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 18-289-Klentrou

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Inflammatory Response

Clinical Trials on Greek Yogurt

3
Subscribe